-

05:32:28 AM

NWBO Stock News

NWBO - Northwest Biotherapeutics Inc

05/10/22 10:19 AM

OTC : NWBO

clinical trial

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, reported that, as previously announced, a presentation entitled "Autologous Tumor Lysate-Loaded

RHEA-AI

neutral

05/04/22 11:35 AM

OTC : NWBO

clinical trial

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, reported that a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for

RHEA-AI

neutral

02/17/22 9:20 AM

OTC : NWBO

Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced commencement of production of its first dendritic cell cancer vaccine for a

RHEA-AI

neutral

12/21/21 9:24 AM

OTC : NWBO

Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing At Sawston, UK Facility

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced that approval has been received from the UK Medicines and Healthcare Products Regulatory

RHEA-AI

very positive

11/29/21 10:38 AM

OTC : NWBO

Northwest Biotherapeutics Announces $15 Million Financing

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced the closing of a $15 million financing on November 22, 2021, which brought the Company's

RHEA-AI

neutral

10/28/21 11:42 AM

Nasdaq, OTC : NWBO

Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced the completion of two key milestones which are required for production of DCVax products

RHEA-AI

neutral

05/12/21 9:16 AM

OTC : NWBO

UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced that an application for certification of the manufacturing facility in Sawston, UK has

RHEA-AI

neutral

05/12/21 4:15 AM

OTC : NWBO

UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced that an application for certification of the manufacturing facility in Sawston, UK has

RHEA-AI

neutral

03/16/21 9:30 AM

OTC : NWBO

Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced that development of the initial production capacity of the Company's Sawston, UK

RHEA-AI

neutral

10/05/20 9:34 AM

OTC : NWBO

Northwest Biotherapeutics Announces Data Lock of Phase III Trial

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced that the database for the Phase III trial of DCVax®-L for Gliobastoma has been

RHEA-AI

neutral